Bilateral Subthalamic Nucleus Lesion Reverses L-Dopa-Induced Motor Fluctuations and Facilitates Dyskinetic Movements in Hemiparkinsonian Rats

Synapse

Volumn 51, Issue 2, 2004, Pages 140-150

  Marin, Concepció ^a,b   Jiménez, Anna ^a   Tolosa, Eduardo ^a   Bonastre, Mercè ^a   Bové, Jordi ^a  

^a INST D INVESTIGACIONS B   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

6 OHDA; Dyskinesias; Motor fluctuations; Parkinson; Subthalamic nucleus

Indexed keywords

BENSERAZIDE; GLUTAMINE; LEVODOPA; OXIDOPAMINE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSKINESIA; FOREBRAIN; INVOLUNTARY MOVEMENT; MALE; MONKEY; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIAS; FUNCTIONAL LATERALITY; LEVODOPA; MALE; MOTOR ACTIVITY; MOVEMENT; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; STEREOTYPED BEHAVIOR; SUBTHALAMIC NUCLEUS; TIME FACTORS;

EID: 0347862712     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10291     Document Type: Article

References (57)

1. Alvarez L, Macias R, Guridi J, López G, Alvarez E, Maragoto C, Teijeiro J, Torres A, Pavon N, Rodríguez-Oroz MC, Ochoa L, Hetherington H, Juncos J, DeLong MR, Obeso JA. 2001. Dorsal subthalatomy for Parkinson's disease. Mov Disord 16:72-78.
2. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. 1991. Lesions of the subthalamic nucleus for the alleviation of 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 4:288-292.
3. Barlas O, Hanagasi HA, Imer M, Sahin HA, Sencer S, Emre M. 2001. Do unilateral ablative lesions of the subthalamic nucleus in parkinsonian patients lead to hemiballism? Mov Disord 16:306-310.
4. Baron MS, Wichmann T, Ma D, DeLong MR. 2002. Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J Neurosci 22:592-599.
5. Benabid AL, Benazzouz A, Limousin P, Koudise A, Krack P, Piallat B, Pollak P. 2000. Dyskinesias and the subthalamic nucleus. Ann Neurol 47(Suppl 1):S189-S192.
6. Bergman H, Wichmann T, DeLong MR. 1990. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438.
7. Bhatt MH, Doshi PK. 2000. Subthalamic nucleus lesioning for advanced Parkinson's disease. Mov Disord 15(Suppl 3):P348.
8. Biggs CS, Fowler LJ, Whitton PS, Starr MS. 1997. Extracellular levels of glutamate and aspartate in the entopeduncular nucleus of the rat determined by microdialysis: regulation by striatal dopamine D-2 receptor via the indirect striatal output pathway? Brain Res 753:163-175.
9. Blanchet PJ, Konitsiotis S, Chase TN. 1998. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798-802.
10. 2A antagonist administration reverses but not prevents levodopa-induced motor alterations in parkinsonian rats. Synapse 46:251-257.
11. Burbaud P, Gross C, Benazzouz A, Coussemacq M. 1995. Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Exp Brain Res 105:48-58.
12. Carpenter MB, Whittier JA, Mettler FA. 1950. Analysis of choreoic hyperkinesias in the rhesus monkey. J Comp Neurol 92:293-322.
13. Cenci MA, Lee CS, Björklund A. 1998. L-Dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706.
14. Chen C, Lee S, Wu T, Chen C, Huang C, Lu C. 2002. Hemiballism after subthalamotomy in patients with Parkinson's disease: report of 2 cases. Mov Disord 17:1367-1371.
15. Crossman AR, Mitchell IJ, Sambrook MA, Jackson A. 1988. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. Brain 111:1211-1233.
16. Delfs JM, Ciaramitaro VM, Parry TJ, Chesselet MF. 1995. Subthalamic nucleus lesions: widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J Neurosci 15:6562-6575.
17. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
18. Doshi P, Bhatt M. 2002. Hemiballismus during subthalamic nucleus lesioning. Mov Disord 17:848-849.
19. Engber TM, Papa SM, Boldry RC, Chase TN. 1994. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5:2586-2588.
20. Figueiras-Mendez R, Marin-Zarza F, Molina JA, Jiménez-Jimé nez FJ, Orti-Pareja M, Magarinos C, López-Pino A, Martínez V. 1999. Subthalamic nucleus stimulation improves directly levodopa induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 66:549-550.
21. Guridi J, Luquin MR, Herrero MT, Obeso JA. 1993. The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease. Mov Disord 4:421-429.
22. Guridi J, Herrero MT, Luquin MR, Guillen J, Ruberg M, Laguna J, Vila M, Javoy-Agid F, Agid Y, Hirsch EC, Obeso JA. 1996. Subthalatomy in parkinsonian monkeys: behavioral and biochemical analysis. Brain 119:1717-1727.
23. Hamada I, DeLong MR. 1992. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 68:1850-1858.
24. Henry B, Fox SH, Crossman AR, Brotchie JM. 2001. μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 171:139-146.
25. Honey CR, Shen H. 1998. Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in subthalamic nucleus. Neurosci Lett 249:151-154.
26. Jiménez A, Marin C, Bonastre M, Tolosa E. 1999. Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism. Brain Res 839:190-193.
27. Kumar R, Lozano AM, Sime E, Halket E, Lang AE. 1999. Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. Neurology 53:561-566.
28. Lee MS, Marsden CD. 1994. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord 9:493-507.
29. Lee CS, Cenci MA, Schulzer M, Björklund A. 2000. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123:1365-1379.
30. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchinson WD, Lozano AM. 2001. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 86:249-260.
31. Limousin P, Pollak P, Benazzouz A, Hoffman D, Le Bas JF, Broussolle E, Pret J, Benabid AL. 1995. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91-95.
32. Limousin P, Pollak P, Hoffmann D, Benazzouz A, Pret JA, Benabid AL. 1996. Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients. Mov Disord 11:231-235.
33. Linazasoro G, Rodríguez-Oroz MC, Obeso JA, et al. 1997. Deep brain stimulation changes the magnitude of the motor response to levodopa in Parkinson's disease: pathophysiological implications. Soc Neurosci Abstr 25:1013.
34. Lozano AM. 2001. The subthalamic nucleus: myth and opportunities. Mov Disord 16:183-184.
35. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. 1996. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 736:202-205.
36. Marin C, Jiménez A, Bonastre M, Chase TN, Tolosa E. 2000. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats. Synapse 36:267-274.
37. Marin C, Jiménez A, Vila M, Bonastre M, Hirsch EC, Agid Y, Tolosa EC. 2001. LY293558, an AMPA glutamate receptor antagonist prevents and reverses levodopa-induced motor fluctuations in parkinsonian rats. Synapse 42:40-47.
38. Marsden CD. 1994. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17(Suppl 2):S32-S44.
39. Merims D, Ziv I, Djaldetti R, Melamed E. 1999. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet 353:1764-1765.
40. Molinuevo JL, Valldeoriola F, Tolosa E, Rumià J, Valls-Solé J, Roldán H, Ferrer E. 2000. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson's disease. Arch Neurol 57:983-988.
41. Nutt JG, Rufener SL, Carter JH, Anderson VC, Pahwa R, Hammerstad JP, Burchiel KJ. 2001. Interactions between deep brain stimulation and levodopa in Parkinson's disease. Neurology 57:1835-1842.
42. Obeso JA, Guridi J, DeLong M. 1997. Surgery for Parkinson's disease. J Neurol Neurosurg Psychiatry 62:2-8.
43. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow C W. 2000. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23(Suppl):S8-S19.
44. Papa SM, Chase TN. 1996. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 39:574-578.
45. Papa SM, Engber TM, Chase TN. 1994. Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69-74.
46. Paxinos G, Watson C. 1982. The rat brain in stereotaxic coordinates. New York: Academic Press.
47. Pearce RKB, Jackson M, Smith L, Jenner P, Marsden CD. 1995. Chronic L-Dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets (Callithrix jacchus). Mov Disord 10:731-740.
48. Pelled G, Bergman H, Goelman G. 2002. Bilateral overactivation of the sensorimotor cortex in the unilateral rodent model of Parkinson's disease. 1. Functional magnetic resonance imaging study. Eur J Neurosci 15:389-394.
49. Roedter A, Winkler C, Samii M, Walter GF, Brandis A, Nikkhah G. 2001. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions, evidence for interhemispheric functional coupling of the two nigrostriatal pathways. J Comp Neurol 432:217-229.
50. Salin P, Manrique C, Forni C, Kerkerian-Le Goff L. 2002. High-frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the basal ganglia in the rat. J Neurosci 22:5137-5148.
51. Shannon KM. 1990. Hemiballismus. Clin Neuropharmacol 13:413-425.
52. Steiner H, Kitai ST. 2001. Unilateral striatal dopamine depletion: time-dependent effects of cortical fuction and behavioural correlates. Eur J Neurosci 14:1390-1404.
53. Verhagen-Metman L, Mouradian MM, Chase TN. 1996. Altered levodopa dose-response profile following pallidotomy. Neurology 46(Suppl 2):A416.
54. Verhagen-Metman L, Del Dotto P, Van der Munckhof P, Fang J, Chase TN. 1998a. Amantadine as a treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326.
55. Verhagen-Metman L, Del Dotto P, Natté R, Van der Munckhof P, Chase TN. 1998b. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 5:203-206.
56. Wichmann T, DeLong MR. 1996. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 6:751-758.
57. Windels F, Bruet N, Popupard A, Urbain N, Chouvet G, Feuerstein C, Savasta M. 2000. Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. Eur J Neurosci 12:4141-4146.